217 related articles for article (PubMed ID: 29899574)
1. Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.
Solano C; Giménez E; Albert E; Mateo EM; Gómez M; Goterris R; Pérez A; Amat P; Hernández-Boluda JC; Poch M; Piñana JL; Navarro D
Bone Marrow Transplant; 2019 Jan; 54(1):90-98. PubMed ID: 29899574
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment.
Solano C; Vázquez L; Giménez E; de la Cámara R; Albert E; Rovira M; Espigado I; Calvo CM; López-Jiménez J; Suárez-Lledó M; Chinea A; Esquirol A; Pérez A; Bermúdez A; Saldaña R; Heras I; González-Huerta AJ; Torrado T; Batlle M; Jiménez S; Vallejo C; Barba P; Cuesta MÁ; Piñana JL; Navarro D;
Bone Marrow Transplant; 2021 Jun; 56(6):1281-1290. PubMed ID: 33319853
[TBL] [Abstract][Full Text] [Related]
3. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide.
Huntley D; Giménez E; Pascual MJ; Hernández-Boluda JC; Gago B; Vázquez L; Piñana JL; García M; Pérez A; Serrano D; Hernández M; Albert E; Solano C; Navarro D
Transpl Infect Dis; 2020 Feb; 22(1):e13206. PubMed ID: 31677215
[TBL] [Abstract][Full Text] [Related]
4. Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes.
Talaya A; Giménez E; Piñana JL; Albert E; Hernández-Boluda JC; Pérez A; Torres I; Solano C; Navarro D
J Med Virol; 2019 Jun; 91(6):1128-1135. PubMed ID: 30735250
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.
Solano C; Giménez E; Piñana JL; Albert E; Vinuesa V; Hernández-Boluda JC; Amat P; Navarro D
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28471073
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients.
Talaya A; Giménez E; Vinuesa V; Pérez A; Amat P; Piñana JL; Albert E; Hernández-Boluda JC; Solano C; Navarro D
Med Microbiol Immunol; 2019 Aug; 208(3-4):405-414. PubMed ID: 30911925
[TBL] [Abstract][Full Text] [Related]
7. Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies.
Huntley D; Talaya A; Giménez E; Martínez A; Hernández-Boluda JC; Hernani R; Torres I; Alberola J; Albert E; Piñana JL; Solano C; Navarro D
Biol Blood Marrow Transplant; 2020 May; 26(5):972-977. PubMed ID: 32007638
[TBL] [Abstract][Full Text] [Related]
8. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
Giménez E; Guerreiro M; Torres I; Aguilar C; Albert E; Hernández-Boluda JC; Hernani R; Pérez A; Amat P; Piñana JL; Montoro J; Solano C; Navarro D
Transpl Infect Dis; 2023 Apr; 25(2):e14021. PubMed ID: 36748748
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies.
Muñoz-Cobo B; Solano C; Costa E; Bravo D; Clari MÁ; Benet I; Remigia MJ; Montoro J; Navarro D
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1602-11. PubMed ID: 21871245
[TBL] [Abstract][Full Text] [Related]
10. The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.
Vinuesa V; Bracho MA; Albert E; Solano C; Torres-Puente M; Giménez E; González-Candelas F; Navarro D
J Gen Virol; 2017 Oct; 98(10):2530-2542. PubMed ID: 28874227
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
Guglieri-Lopez B; Perez-Pitarch A; Garcia-Cadenas I; Gimenez E; Barba P; Rabella N; Hernandez-Boluda JC; Fox L; Valcarcel D; Esquirol A; Ferriols-Lisart R; Sierra J; Solano C; Navarro D; Martino R; Piñana JL
Biol Blood Marrow Transplant; 2019 May; 25(5):1022-1030. PubMed ID: 30639821
[TBL] [Abstract][Full Text] [Related]
12. An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.
Talaya A; Giménez E; Pascual MJ; Gago B; Piñana JL; Hernández-Boluda JC; Vázquez L; García M; Serrano D; Hernández M; Albert E; Solano C; Navarro D
Med Microbiol Immunol; 2020 Feb; 209(1):15-21. PubMed ID: 31478067
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
[TBL] [Abstract][Full Text] [Related]
14. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
16. The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.
Albert E; Solano C; Giménez E; Focosi D; Pérez A; Macera L; Piñana JL; Boluda JCH; Maggi F; Navarro D
Bone Marrow Transplant; 2018 Feb; 53(2):180-187. PubMed ID: 29084205
[TBL] [Abstract][Full Text] [Related]
17. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus.
Chen Y; Xu LP; Liu KY; Chen H; Chen YH; Zhang XH; Wang Y; Wang FR; Han W; Wang JZ; Yan CH; Huang XJ
J Clin Virol; 2016 Feb; 75():10-5. PubMed ID: 26735213
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients.
Pascual T; Solano C; Torres I; Talaya A; Giménez E; Vinuesa V; Piñana JL; Hernández-Boluda JC; Pérez A; Navarro D
J Med Virol; 2018 Aug; 90(8):1375-1382. PubMed ID: 29663435
[TBL] [Abstract][Full Text] [Related]
20. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
